EE300 Cost Effectiveness of Momelotinib Vs Other Treatments for Myelofibrosis from a US Payer Perspective
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.599
https://www.valueinhealthjournal.com/article/S1098-3015(24)00714-9/fulltext
Title :
EE300 Cost Effectiveness of Momelotinib Vs Other Treatments for Myelofibrosis from a US Payer Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00714-9&doi=10.1016/j.jval.2024.03.599
First page :
Section Title :
Open access? :
No
Section Order :
10074